Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patientsMatthew R. Wilson, Fiona Miall, Marie‐Pierre Moles‐Moreau et al.|UCL Discovery (University College London)|2022Cited by 76
Outcomes after first-line immunochemotherapy for primary mediastinal B-cell lymphoma: a LYSA studyVincent Camus, Hervé Tilly, Marie‐Pierre Moles‐Moreau et al.|Blood Advances|2021Cited by 51
R-CHOP14 As a Standard of Care in Primary Mediastinal B Cell Lymphoma: A 10-YEARS Experience of Lysa CentersVincent Camus, Hervé Tilly, Hélène Monjanel et al.|Blood|2020Cited by 3
Impact of Body Composition on Treatment Toxicity and Outcomes in Patients With Primary Mediastinal Large B‐Cell LymphomaJuliette Pénichoux, Vincent Camus, Jérôme Paillassa et al.|Hematological Oncology|2025Cited by 1
OUTCOMES AFTER FIRST‐LINE IMMUNOCHEMOTHERAPY FOR PRIMARY MEDIASTINAL B CELL LYMPHOMA PATIENTS: A LYSA STUDYVincent Camus, Hervé Tilly, Alexandra Traverse‐Glehen et al.|Hematological Oncology|2021Cited by 0